BRCA 2021: A Vision of the Future represents a unique opportunity to look at all aspects of breast and ovarian cancer, and in particular the susceptibility genes, BRCA1 and BRCA2, which are responsible for a considerable fraction of early-onset breast cancer.
Clinicians and researchers from over 25 countries will gather virtually for the eighth edition of this event which has come to be recognized as THE major international conference in the world that covers specific targeted therapies for hereditary cancer.
Topics covered will include population-based approaches to genetic testing and risk assessment, early diagnosis of breast and prostate cancer in BRCA1 or BRCA2 heterozygotes, new developments in treatment of HBOC, rarer moderate to highly penetrant breast and ovarian cancer syndromes, insight from large datasets of women with breast cancer, the other BRCA-associated tumors, and the ethico-legal issues around usage of genomic data, to name just a few.
The Programme Committee is pleased to issue an extended Call for Abstracts for poster presentations. Note: All abstracts that were accepted (for oral and poster presentation) at the 2020 Symposium that was postponed have been offered the opportunity to present in 2021 without having to resubmit. All will have until March 12, 2021 to revise their abstract if they so wish, prior to publication. In addition, the deadline to submit new abstracts for poster presentation has been extended to March 12, 2021. Interested participants are invited to submit abstracts on topics related to hereditary breast, ovarian, prostate and pancreas cancer. Submissions are welcome from all disciplines. Click here to go to the Call for Abstracts page.
Deadline for Oral Abstract Submissions: December 6, 2019
Deadline to submit revisions to abstracts that were accepted in 2020: March 12, 2021
Deadline for New Poster Abstract Submissions: March 12, 2021
The tradition of a one day public conference for those Living with BRCA, their families and friends, will continue as part of our commitment to educate and inform the wider population about BRCA 1/2. Click here.